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ABSTRACT
Introduction Antibiotics are essential to treat infections 
during pregnancy and to reduce both maternal and 
infant mortality. Overall use, but especially non- indicated 
use, and misuse of antibiotics are drivers of antibiotic 
resistance (ABR). High non- indicated use of antibiotics for 
uncomplicated vaginal deliveries is widespread in many 
parts of the world. Similarly, irrational use of antibiotics 
is reported for children. There is scarcity of evidence 
regarding antibiotic use and ABR in Lao PDR (Laos). The 
overarching aim of this project is to fill those knowledge 
gaps and to evaluate a quality improvement intervention. 
The primary objective is to estimate the proportion 
of uncomplicated vaginal deliveries where antibiotics 
are used and to compare its trend before and after the 
intervention.
Methods and analysis This 3- year, prospective, 
quasiexperimental study without comparison group 
includes a formative and interventional phase. Data 
on antibiotic use during delivery will be collected from 
medical records. Knowledge, attitudes and reported 
practices on antibiotic use in pregnancy, during delivery 
and for children, will be collected from women through 
questionnaires. Healthcare providers’ knowledge, 
attitudes and practices of antibiotics administration for 
pregnant women, during delivery and for children, will 
be collected via adapted questionnaires. Perceptions 
regarding antibiotics will be explored through focus group 
discussions with women and individual interviews with key 
stakeholders. Faecal samples for culturing of Escherichia 
coli and Klebsiella spp. and antibiotic susceptibility testing 
will be taken before, during and 6 months after delivery to 
determine colonisation of resistant strains. The planned 
intervention will comprise training workshops, educational 
materials and social media campaign and will be 
evaluated using interrupted time series analysis.
Ethics and dissemination The project received ethical 
approval from the National Ethics Committee for Health 
Research, Ministry of Health, Laos. The results will be 
disseminated via scientific publications, conference 
presentations and communication with stakeholders.
Trail registration number ISRCTN16217522; Pre- results.
INTRODUCTION
Antibiotics are life- saving medicines and 
important interventions in health systems.1 
Misuse and overuse of antibiotics contribute 
to development and spread of antibiotic 
Strength and limitations of this study
 ► This is the first study that addresses perceptions, 
knowledge, attitudes and practices regarding an-
tibiotic use and antibiotic resistance (ABR) among 
pregnant women and mothers of children under 2 
and healthcare providers (HCPs) in Lao PDR, using 
interviews and records reviews.
 ► This study is also the first to collect data on ABR car-
riage patterns of Escherichia coli and Klebsiella spp. 
among healthy pregnant women and their children 
in these settings.
 ► We will generate evidence on knowledge of HCPs 
and community, and possibly decrease unnecessary 
use of antibiotics (especially for uncomplicated vag-
inal delivery), therefore contribute to containing the 
spread of ABR.
 ► The broad range of stakeholders such as research-
ers, HCPs, local authorities and policy- makers in-
volved in the study may contribute to the effective 
implementation of the intervention and development 
of national and local prescribing guidelines.
 ► The study participants, both pregnant women and 
HCPs may tend to answer the questions about their 
practices in a way they think it is expected, therefore 
social desirability bias cannot be overruled.
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resistance (ABR)—one of the most pressing global health 
threats.2 3 ABR contributes to increased morbidity, 
mortality and healthcare costs, and disproportionately 
impacts poorer countries where access to, and use of, 
antibiotics is frequently coupled with a high prevalence of 
infectious disease, exacerbating global economic inequal-
ities.4 ABR is a complex process driven by many inter-
related factors.5–7 To effectively mitigate the emergence 
and dissemination of ABR, pragmatic and collaborative 
actions are required including behavioural change inter-
ventions and infections prevention and control measures.
Antibiotics are essential to treat common infections 
during pregnancy, to prevent maternal and neonatal 
infections during delivery, and to treat infections arising 
from surgical wounds after caesarean sections.8 9 Reports 
from Canada and The Netherlands showed that approx-
imately 20%–25% of women received antibiotics during 
pregnancy.10 11 However, during pregnancy, the use of 
any medicines and specifically antibiotics is a risk- versus- 
benefit decision and needs to be carefully considered.
The use of antibiotics during the pregnancy delays 
final infant’s gut colonisation and during that time the 
infants are more susceptible to infections and to immune- 
mediated diseases.12 13 This might result in increased anti-
biotic consumption in childhood and ultimately leads to 
increased ABR.
Use of antibiotics for uncomplicated vaginal delivery 
is generally not recommended14; however, some reports 
show alarmingly high use in these situations. For instance, 
data from India showed that 87% of women who had 
vaginal delivery received antibiotics and 28% were 
discharged from the hospital with prescribed antibiotics 
regardless the mode of the delivery.15
Therefore, the use of antibiotics by the vulnerable 
groups, for example children and pregnant women, 
has to be carefully monitored and evaluated bearing in 
mind side effects such as nausea, diarrhoea or quinolone 
toxicity to the developing skeletal system.
The faecal microbiota serves as a reservoir for ABR 
genes. Exposure of commensals such as Escherichia coli to 
antibiotics may increase the carriage levels of resistance 
genes and facilitate their spread to pathogenic strains 
of bacteria.16 So far, a few studies have looked at ABR in 
bacteria isolated from humans in Lao PDR (Laos), mainly 
in the capital city Vientiane or province. One study from 
2011 showed colonisation of Enterobacteriaceae producing 
extended spectrum beta- lactamase (ESBLs) among 23% 
of healthy pre- school children.17 Another study from 
one of the major hospitals in Vientiane shows increasing 
occurrence of ESBLs in bloodstream E. coli isolates.18 
In contrast, case reports of colistin resistance (the last 
antibiotic option for multidrug resistant Gram- negative 
bacteria) showed a potentially severe situation relating 
to ABR in the country; however, a structured study to 
support these results is needed.19
While there is some evidence of irrational antibiotic 
use, studies on antibiotic use among children in Laos 
have, to our knowledge, not been conducted. Also, data 
regarding antibiotic use during pregnancy and childbirth 
in Laos are scarce. Data from 200820 showed that from 300 
women with normal vaginal deliveries, 79% delivered at 
home, of those 25% used antibiotics and among women 
who delivered in hospitals 79% received antibiotics. Since 
then, the quality of antenatal care (ANC) has improved, 
is free of charge and attendance to ANC has increased. 
Data from Lao Social Indicators survey from 2017 show 
that 65% of women delivered at health facilities and more 
than 80% attended ANC at least once.
In this study protocol, we present the scheme of data 
collection, plan for data analysis and implementation 
and evaluation of the intervention targeted to healthcare 
providers (HCPs) and community.
The project Containment of Antibiotic REsistance—
measures to improve antibiotic use in pregnancy, child-
birth and young children (CAREChild) is an international 
project between partner institutions in Laos and Sweden 
that aims to understand and improve antibiotic use in 
relation to pregnancy, childbirth and early childhood in 
Laos with the long- term aim to contain ABR.
The specific objectives are to:
 ► Estimate the proportion of uncomplicated vaginal 
deliveries where antibiotics are used and to compare 
its trend before and after the intervention.
 ► Explore and assess perceptions, knowledge, atti-
tudes and reported practice of pregnant women, and 
mothers of children under 2 regarding antibiotic use 
and resistance in relation to pregnancy, childbirth 
and children under 2 years of age.
 ► Explore and assess perceptions, knowledge, attitudes, 
reported practice, as well as actual practice of HCPs 
regarding antibiotic use and resistance in relation to 
pregnancy, childbirth and children under 2 years of 
age.
 ► Estimate the ABR situation with focus on ESBLs 
producing and multi- drug resistant E. coli and Kleb-
siella spp. carriage in faecal samples among women 
and children.
 ► Develop and test interventions aimed at HCPs and 
community members to improve use of antibiotics.
We hypothesise that the use of antibiotics for uncompli-
cated vaginal deliveries is high and that the educational 
intervention will reduce the proportion of antibiotics 
administered and lead to an improvement in knowledge 
regarding antibiotic use and ABR of both community and 
HCPs.
METHODS AND ANALYSIS: STUDY DESIGN AND DATA 
COLLECTION
Study design
This is a 3- year, prospective, quasiexperimental, inter-
ventional study with both continuous and repeated data 
collection. The study will start with an extensive forma-
tive phase leading to the development of an intervention, 
which will be evaluated through time series analysis. In 
the formative phase potential barriers and facilitators 
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for implementing the intervention will be identified. 
Collected data will inform about the context, adaptations 
and response to change of HCPs and the community 
behaviours in relation to antibiotic use. Quantitative and 
qualitative data will be collected before (formative phase) 
and after the intervention at all health facilities and in the 
community.
Study settings
The study will be conducted in Laos, a lower middle- 
income country in Southeast Asian with approximately 
7 million inhabitants and relatively low population 
density.21 Laos has 17 provinces, 1 capital city, 148 
districts and 8459 villages. Around two- thirds of the 
population lives in rural areas and relies on agricul-
tural work, specifically rice farming. Individual villages 
in Laos tend to be home to a particular ethnic group.22 
Feuang and Vang Vieng districts in Vientiane province 
in the central part of the country will be selected as study 
areas based on variations in background characteristics, 
representing different ethnic minority population and 
for feasibility reasons. In order to better understand the 
current situation of antibiotic use and ABR, all levels of 
healthcare facilities, that is Vientiane provincial hospital, 
two district hospitals and six health centres in each of 
the two study districts, will be purposively selected as the 
study sites. To avoid contamination, the qualitative part 
of the study before the intervention will be conducted 
in Thulakhom district (Vientiane province), which is 
outside the study area. For the same reason the pilot 
study will take place in Phonehong (Vientiane province) 
and Santhong districts (Vientiane capital). List of the 
study sites can be obtained on request from the local 
principal investigator.
Inclusion criteria for women
1. All pregnant women in the third trimester, who after 
the enrolment plan to stay in the area for the next 
24 months, who are willing to participate in the study, 
and whose infants are born during the study period.
Inclusion criteria for HCPs
1. All medical doctors, assistant doctors, midwives, nurs-
es, pharmacists, assistant pharmacists at the Vientiane 
provincial hospital, district hospitals or health centres 
in Feuang or Vang Vieng as well as drug sellers (only 
pharmacists and assistant pharmacists) at private phar-
macies in these districts.
2. For individual qualitative interviews: private providers 
(in private clinics and pharmacies) in the study area, 
representatives from central level such as Ministry of 
Health, university and professional organisations in 
addition to providers from the public healthcare facil-
ities, HCPs and policy- makers from the Maternal and 
New- born Hospital in Vientiane capital, where women 
from different parts of the country come for ANC and 
consultation.
Data collection: pilot study
Building on the research team’s experiences15 23 and 
expertise of the local team, the data collection instru-
ments were developed in English, adapted for different 
target groups and translated into Lao. In March 2019, 
a pilot study was conducted to field test the data collec-
tion instruments and procedures to train data collec-
tors. In total, 30 questionnaires on knowledge, attitudes 
and reported practices were pilot tested with 10 HCPs, 
10 pregnant women and 10 mothers of a child under 2. 
In parallel, to capture perceptions, focus group discus-
sion (FGD) and qualitative interview guides were tested 
during one FGD with mothers and one FGD with preg-
nant women and four interviews with HCPs. Preliminary 
results from the pilot test have guided the final version 
of data collection instruments and shed light on possible 
components and acceptability of the intervention. A 
summary of the data collection instruments that will be 
used in the study is presented in table 1.
Quantitative data collection
Repeated structured interviews on knowledge, attitude 
and reported practice regarding antibiotic use, ABR and 
antibiotic side effects will be performed with women at 
three timepoints, that is before the intervention (during 
pregnancy and 6 months after delivery) and after the 
intervention.
HCPs will be interviewed about their knowledge, atti-
tudes and reported practice regarding antibiotic use for 
pregnant women, delivery and for children before and 
after the intervention. Simultaneously, data on antibiotic 
use during delivery will be continuously collected from 
patient records in all included health facilities.
The baseline interviews with expecting mothers and 
HCPs will be performed at ANC visit. The follow- up 
questionnaires with the women after delivery will be 
performed during the routine vaccination scheme visit or 
if not possible in the household. HCPs are interviewed at 
their workplace.
To capture additional information on self- reported use 
of antibiotics, several forms will be attached to the ANC 
booklet—a booklet that women receive at the beginning 
of pregnancy and where all pregnancy related information 
are recorded by HCP (table 1). Pregnant women will be 
asked to report all medicines taken regularly to improve 
overall health status, prevent disease or treat chronic 
condition (eg, folic acid, iron, herbs) or occasionally for 
any episode of illness (eg, antibiotic, paracetamol, herbs). 
Similarly, a regular and occasional use will be reported by 
mothers for their children. Additionally, we will collect 
data on the last clinical examination of pregnant woman 
and/or a child. The forms will be filled by an HCP at each 
occasion when a pregnant woman and/or child seeks for 
healthcare with symptoms of illness. The forms will be 
collected monthly from the ANC booklet by a designated 
person at each healthcare facility, stored in a secure place 
and then collected by the study team.
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Qualitative data collection
FGDs will be organised to discuss women’s perceptions 
of antibiotic use, ABR and side effects during pregnancy, 
childbirth and for children. A range of stakeholders 
(HCPs and policy- makers) will be individually inter-
viewed to explore their views on antibiotic use, ABR, side 
effects of antibiotic use during pregnancy, childbirth and 
for children as well as infection prevention and control 
measures.
Before the intervention 6 FGDs (3 groups with 29 preg-
nant women and 3 groups with 26 mothers with children 
under 2 years of age) will be organised in Thulakhom 
district, and approximately 30 HCPs will participate in 
the individual qualitative interviews (approximately 9 at 
central and provincial level, and 12 at district level). After 
the intervention the FGDs and individual interviews will 
be conducted with similar number of participants until 
data saturation is reached. The FGDs and individual 
interview guides themes are presented in online supple-
mental appendix 1.
Recruitment
The pregnant women will be identified via the local 
health registry of ANC, and invited to participate during 
their ANC visit. All HCPs working in the study sites will be 
invited to participate and will be notified about the study 
via local health staff name list. Women who will partici-
pate in FGDs before the intervention will be identified 
Table 1 Data collection instruments used in the Containment of Antibiotic REsistance—measures to improve antibiotic use in 
pregnancy, childbirth and young children project
Data collection 
instrument Target data source/participant
Timepoint and place of data 
collection Outcome variable
Structured interview 1. Pregnant women
2. Mothers
3. HCPs
1. At pre- intervention phase, 
collected during ANC visit
2. At pre- intervention phase, 
collected 6 months after the 
delivery during a vaccination 
visit; and at post- intervention 
phase, collected during home 
visit
3. At pre- intervention and at post- 
intervention phase, collected at 
the health facility
Knowledge, attitudes and 
self- reported practices 
regarding antibiotic use and 
resistance




1. At pre- intervention phase, 
attached to the ANC booklet and 
filled in on a monthly basis
2. At pre- and post intervention 
phase, attached to ANC booklet
1. Self- reported practice on 
medicines used during 
pregnancy
2. Self- reported practice on 





1. At pre- intervention phase, during 
consultation with HCP
2. At pre- and post- intervention 
phase, during consultation with 
HCP
1. Medicines prescribed to 
pregnant women while 
seeking medical help
2. Medicines prescribed 
to a child while seeking 
medical help
Records review form Pregnant women Records review in the included 
health facilities, 12 months pre- and 





All relevant HCPs (doctors, 
nurses, midwifes, private 
providers), drug sellers and 
policy- makers (Ministry of 
Health, members of professional 
association, university)
At pre- and post- intervention 
phase, interviews at the workplace 
of key stakeholder
Perceptions of HCPs and 
policy- makers towards 
antibiotic administration to 
pregnant women, during 






1. At pre- intervention (women 
selected from outside the study 
area)
2. At pre- intervention (women 
selected from outside the study 
area), and at post- intervention 
(women from the study area)
Perceptions of pregnant 
women and mothers 
regarding antibiotic use and 
resistance during pregnancy, 
delivery and for children 
under 2
ANC, antenatal care; HCPs, healthcare providers.
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during postpartum visit and/or child vaccination visit 
and approached by local health staff. Stakeholders for 
individual qualitative interviews will be identified and 
recruited via local health staff name list.
Data collection performance
The data collection team comprises: 4 Master’s students 
from Lao Tropical and Public Health Institute, 4 staff 
members from the same Institute and 4 staff members 
from the University of Health Science in Vientiane who 
speak the local language. All data collectors will partici-
pate in a 1- week long training shortly before the initiation 
of data collection. The training will consist of lectures 
on qualitative and quantitative methodology, practical 
sections on using electronic platform for data collection 
with tablets, practical session on qualitative interviews, 
standard operating procedures for each question, micro-
biology samples collection and field management. Data 
collectors will conduct both quantitative and qualitative 
interviews and act as moderators and note takers during 
FGDs.
METHODS AND ANALYSIS: INTERVENTION
Educational intervention
The results from the pilot study and formative phase, 
combined with the experience in educational interven-
tions of the research team24 25 will feed in the develop-
ment of a contextual educational intervention. The 
educational package aims to decrease unnecessary 
antibiotic use for uncomplicated vaginal deliveries and 
during pregnancy, increased knowledge and indirectly 
limit the spread of ABR. The educational intervention 
will be conducted in Feuang district due to feasibility 
reason and faster availability of baseline data, will start 
immediately after follow- up data collection and will 
last 3 months. After completion of the intervention the 
research team aims to sustain some of the intervention 
activities, for example, posters display. The project time-
line is presented in figure 1.
The intervention will consist of several components 
tailored to HCPs and community:
(1) A participatory, iterative process- based model for 
improvement will be used as a conceptual framework for 
developing, testing and implementing changes in the 
proposed intervention. The Plan–Do–Study–Act cycle 
allows to test out changes on a small scale, building on 
the learning from these cycles in a structured way before 
the full- scale implementation.26
Results from the formative phase (started in September 
2019) showed that almost all HCPs have access to a mobile 
phone and would accept an intervention provided via 
online platforms or social media. Although there are 
several treatment guidelines in place at the national level, 
there are no specific guidelines regarding intrapartum 
antibiotic use. Therefore, several interventional compo-
nents will be targeted to HCPs: (a) Educational workshops 
with a key content on selection of antibiotics per indica-
tion, use of broad versus narrow spectrum antibiotics and 
Figure 1 Timeline of the project. KAP, knowledge, attitude and practice.
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feedback on qualitative and quantitative findings. Work-
shops will be delivered by a facilitator using power point, 
case studies, presentation of support tools (eg, alcohol- 
based hand rub) and role playing. These workshops will 
take place at several occasions during 3- month interven-
tion period and the facilitator will use Train the Trainers 
approach. (b) Educational tools (leaflets, handouts) 
regarding antibiotic use during pregnancy, childbirth 
and for children, ABR, infection prevention and control 
will be developed and provided by the study team to each 
HCPs via both traditional (at healthcare facilities) and 
online channels. (c) Short, acceptable messages will be 
developed and sent regularly from a trusted source (i.e. 
Lao Tropical and Public Health Institute) via WhatsApp 
to all HCPs who participated in the workshops.
In addition, a revision of existing curricula for HCPs 
educational tracks and if needed initiation of recur-
rent training regarding intrapartum antibiotic use will 
take place. A collaboration with national Obstetrics and 
Gynaecology Association will be initiated to work on the 
development of local prescribing guidelines.
(2) Women are usually the main caregivers of the 
children and often the main decision- makers regarding 
healthcare seeking behaviour, and have a great impact on 
the use of antibiotics among pregnant women and chil-
dren. Simple and inexpensive interventions using short 
text messages have been widely used in low- income and 
middle- income countries and some of them showed to 
be a potent tool for behavioural change.27–30 The results 
from the formative phase showed that initially planned 
mHealth intervention will not be feasible to target 
community members. Mobile phone ownership is as low 
as 30% among the rural population and the male, head 
of household, often is in charge of the phone. Therefore, 
the following intervention components will be used: 
(a) Educational workshops that will cover broad range 
of topics for example, antibiotic use during pregnancy, 
hygiene and self- care during pregnancy and delivery 
(in case of home deliveries) and after delivery, breast-
feeding and other feeding practices, vaccinations, caring 
for a sick child, antibiotic use for children. The work-
shops will be organised in the villages at several occasion 
during the intervention period, delivered by a facilitator 
and supported by local health staff. We also aim to ask 
local Lao Women’s Union to support and endorse the 
activities.
(b) Several well- accepted communication channels 
such as posters and radio campaigns to convey the key 
message on prudent antibiotic use during pregnancy 
and for children will be used. Posters will be displayed 
in villages, for example, around intersections or by resi-
dents’ gathering places, such as the door of the super-
market or village clinic or pharmacy, or outer wall of a 
house located on the main road. Radio campaigns will be 
designed and delivered as a short role- playing scenarios, 
for example, newly delivered women and HCPs talking 
about need for antibiotics after delivery in decided broad-
casting time.
Evaluation of the intervention
Primary outcome
The primary outcome of the study is the proportion of 
uncomplicated normal deliveries for which antibiotics 
were used. Data on antibiotic use for each delivery will be 
collected from patient records at included health facilities 
continuously for 12 months before, during and 12 months 
after the intervention. The impact of the intervention will 
be evaluated through time series analysis.
Secondary outcomes
 ► Knowledge, attitudes and reported practices regarding 
antibiotic use during pregnancy and for children and 
ABR of pregnant women and mothers.
 ► Knowledge, attitudes and reported practices regarding 
antibiotic use for pregnant women, during delivery 
and for children and ABR of HCPs.
 ► Proportion of samples with ESBL or multidrug 
resistant producing bacteria and other relevant resist-
ances pattern to tested antibiotics (only pre interven-
tion phase).
 ► Proportion of children under 2 years of age where 
antibiotics have been used.
 ► Proportion of caesarean section deliveries where anti-
biotics are given.
Following the completion of the intervention phase, 
mothers and HCPs will be interviewed again using the 
same questionnaires as at the pre- intervention to evaluate 
the change in their knowledge, attitudes and practices. To 
evaluate if the intervention was carried out as planned and 
detect the strengths and weaknesses of the programme, 
several process indicators data will be collected. We will 
monitor number of participants, number of booklets, 
handouts and posters printed and distributed. A local 
research team will use a process evaluation form to 
monitor the intervention with local partners. After the 
workshops, both HCPs and community members will be 
given a questionnaire to collect their reflections on the 
provided content.
METHODS AND ANALYSIS: MICROBIOLOGY ANALYSIS AND 
METHODS
Microbiology samples collection and analysis
We aim to estimate the prevalence of faecal carriage of 
ESBL producing and multidrug resistant E. coli and Kleb-
siella spp. Rectal swabs will be collected from all pregnant 
women before delivery, during delivery from women 
and their newborn children (meconium) and 6 months 
after delivery from mothers and their children. Should 
taking samples during delivery not be possible, they will 
be taken at home within 7 days after delivery. Rectal swabs 
will be collected at each health facility in Feuang district 
by either HCP or mother herself and transported to 
the district hospital in a cold box with icepack to keep 
temperature around 2°C–4°C. After collecting samples in 
the district hospital, they will be transported to the micro-
biology laboratory of the Mahosot hospital in Vientiane 
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capital, maintaining the cold chain as appropriate. After 
arrival, samples will be stored at 4°C until processing. All 
samples will be processed within 14 days after sampling.
Rectal swabs will be used for culturing on Brilliance 
UTI Agar (bioMerieux), where E. coli will appear as red 
or pink colonies and Klebsiella spp. as dark blue colo-
nies. Species identification will be performed biochemi-
cally. Those confirmed as E. coli or Klebsiella spp. will be 
screened for ESBL using cefpodoxime. The suspected 
ESBL strains will be further tested using ceftazidime with 
and without clavulanic acid and cefotaxime with and 
without clavulanic acid. In the next step, all positive ESBL- 
producing strains will be tested against common antibi-
otics using disk diffusion susceptibility test: ampicillin, 
amoxicillin/clavulanic acid, ceftriaxone, meropenem, 
gentamicin, amikacin, trimethoprim/sulfamethoxazole, 
cefpodoxime, chloramphenicol, ciprofloxacin and tetra-
cycline. Antibiotic susceptibility testing will be performed 
by standardised disk diffusion method (Clinical and 
Laboratory Standards Institute, 2018). In parallel, swabs 
will be cultured on CHROMID CARBA (bioMerieux) for 
detection of carbapenemase- producing Enterobacteriaceae. 
ESBL- producing/CARBA medium isolates of E. coli and 
Klebsiella spp. will be stored at −80°C for future analysis.
METHODS AND ANALYSIS: DATA MANAGEMENT AND ANALYSIS
Electronic data collection, data management and data quality 
control
All quantitative data will be collected and managed 
electronically using Research Electronic Data Capture 
(REDCap)31 tool hosted at Karolinska Institutet. REDCap 
is a secure, web- based application designed to support 
data capture for research studies, providing audit trails 
for tracking data manipulation and export procedures. 
Data collection instruments will be developed in REDCap 
and, where appropriate, consisted predetermined checks 
and range validations. For in- the- field data collection 
purpose, instruments will be exported onto Samsung 
tablets (Samsung Galaxy Tab. 3.V, Seoul, South Korea) 
equipped with mobile internet access. Data collected via 
tablets will be cross- checked before synchronisation with 
the REDCap server. Data collected via paper forms will be 
cross- checked for completeness and entered directly to 
REDCap server by a data key entry person. Data quality 
checks will be run weekly by a data manager who tracks 
information such as form completion, internal consis-
tency, data range and eligibility criteria. Feedback will be 
regularly communicated with data collectors and study 
team to assure consistent, high quality data collection.
Qualitative data will be audio- recorded, transcribed 
verbatim and checked with recorder version.
Sample size
Considering an estimated 79% for the main outcome 
measure of the study (proportion of uncomplicated deliv-
eries in the hospital where antibiotics are given) 20, with a 
95% CI, a sample size of 450 deliveries would allow us to 
have a CI with a width equal to 4%. Therefore, to allow a 
loss to follow- up of 25%, 600 women are included.
Data analysis
Statistical analysis will be performed using STATA V.15.1 
(College Station, Texas, USA). Descriptive analyses will 
include frequencies for categorical variables, mean and 
standard deviation or median and inter- quartile range 
for continuous variables. Chi- square test will be used 
to compare two categorical variables, t- test or Mann- 
Whitney U test will be used to compare a numerical vari-
able in two groups, while when comparing a numerical 
variable among three or more groups Analysis of Variance 
(ANOVA) or Kruskal- Wallis test will be used. Interrupted 
time series analysis will be used to compare the trend in 
the proportion of the primary outcome of interest the 
12 months before the planned intervention and 12 months 
after it.32 Moreover, in order to compare knowledge and 
attitudes of mothers and HCPs (pre–post intervention) 
we will use multilevel mixed effects generalised linear 
models (Stata command meglm) with different family 
distributions according to the outcome distribution 
(Stata option family). Results will be presented as effect 
estimates with 95% CIs and will primarily be done both 
together and separately for each healthcare facility. Inter-
action test will be performed if relevant. P values less than 
0.05 will be considered significant in the final analysis.
Manifest and latent qualitative content analysis will be 
applied for the qualitative data analysis.33
Study status
Data collection started in September 2019 is ongoing 
and will continue until the end of 2021 followed by data 
analysis and dissemination of results. Preliminary results 
obtained from the formative phase supported develop-
ment of the intervention components and are described 
in the methods section.
Due to COVID-19 pandemic, CHROMID CARBA 
(bioMerieux) cannot be continuously delivered to Laos 
and that results in adjustments in the microbiological 
procedures. After arrival to the microbiology laboratory 
of the Mahosot hospital in Vientiane capital, samples are 
stored at −80°C until processing.
ETHICS AND DISSEMINATION
Ethics
The project received ethical approval from the National 
Ethics Committee for Health Research, Ministry of 
Health of Laos (031/NECHR dated 27 March 2019). All 
study participants will receive information about the aim 
of the study and their role as participants and they will be 
asked for a written consent. They will be informed that 
participation is voluntary and that they are free to with-
draw from the study at any time without experiencing any 
repercussions.
The research team will take several measures to assure 
participants’ confidentiality throughout the study. During 
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structured interviews, no information that may compro-
mise participant’s identity will be collected. A unique 
participant’s ID code will be generated for each partici-
pant and will be used for data collection and analysis. The 
unique identifier will be stored separately and accessible 
only to a data manager. Moreover, all participants of the 
FGDs and qualitative interviews will be asked to refrain 
from sharing information about what was said during 
the FDGs and interviews. Although we are aware that 
this cannot be guaranteed from all participants, it will be 
guaranteed from the research team side. The participants 
will be informed that the qualitative interviews and FGDs 
are recorder. All data will be stored in cloud- based repos-
itories. Data safety, sharing and protection will be agreed 
on during consultative meetings in line with national 
legislation.
Risk and benefits for the study participants have been 
carefully considered. During the data collection process, 
we will interview pregnant women and mothers of young 
children about their knowledge, attitudes and practices 
regarding antibiotic use and ABR. There is a risk that 
some questions may be perceived as intimidating and 
cause stress, since women may be afraid that investigators 
are questioning their knowledge and practices. For HCPs, 
participation in the study may cause additional workload 
related to answering interview questions and filling up 
additional forms.
However, we believe that the short- term and long- term 
outcomes of the study overcome the possible risks attrib-
utable to this study. All researchers involved in the study 
will work together to minimise potential risks and stress 
factors for the study participants at the same time assuring 
them of the benefits.
Dissemination plan
Findings from this project will be disseminated to a range 
of stakeholders in addition to traditional peer- reviewed 
international or national journal articles, conference 
presentations (Lao National Health Research Forum), 
consortium meetings, symposia and networking events. 
As part of the project implementation process, we will 
feedback results to local stakeholders, authorities, policy- 
makers and community members via various recognised 
communication channels. The local consortium partners 
will be responsible to assure the successful communica-
tion with relevant stakeholders. In addition, if feasible 
and appropriate dissemination through mass media will 
be done.
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